{"name":"Pluristem Ltd.","slug":"pluristem-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cell therapy","genericName":"Cell therapy","slug":"cell-therapy","indication":"Other","status":"marketed"},{"name":"PLX-PAD","genericName":"PLX-PAD","slug":"plx-pad","indication":"Critical limb ischemia (CLI) / peripheral arterial disease","status":"phase_3"}]}],"pipeline":[{"name":"Cell therapy","genericName":"Cell therapy","slug":"cell-therapy","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PLX-PAD","genericName":"PLX-PAD","slug":"plx-pad","phase":"phase_3","mechanism":"PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms.","indications":["Critical limb ischemia (CLI) / peripheral arterial disease","Acute myocardial infarction (AMI)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxObVlxc3U4MFpkUTZaMmVVWTFRVmV0dkxWei1lUF9qdTJNMGpIaTREdFJQTlZzWVBTMFJBRlF5YXpWX1k2ak5NT2J3elIwLUMtOFUtZGF1ZzFmYVIyaWd2Z3pmMzdTb1FqSjhZemdLaUlnRVQxMlRta0cyMGI0Uko5c2pwWEdUQ1ZzV1BZ0gGQAUFVX3lxTE02UWVvN05VYTI4cjVKWTlCMEtjR2hIX2IyQ1NtVTlVOTV0WTdSMzhFUDM1YnM5VDlMM2N6d052R2tPTWRvVWVXZVQ3Vk5kY05KbVNDNkZtamV3ckw3eDhmQWVKWjVHZXZDNWJMMEUwTGR5QVJJRTc5ckc0R05wNm00TWVHc3F4cm1kMmhxdmIweg?oc=5","date":"2024-11-12","type":"pipeline","source":"BioInformant","summary":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies? - BioInformant","headline":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxObHRZbW5qbUhROVktVlZwYWNoYjRlVEtjME5JVzlWRzFqdlhpLXljMk5BWmRqNXZXbmhpTFpHWlR1QmYtbm5WVEJwQ0xfaVFrTnhvRGNNMnkteHpmRGVvTTNYSnRjY3ZFa0QtLXVSX1Q3VFJLOUFtUTRQTTdhX3ZfWHJ5ZlIwRldIT1VpaER0ZndiekZ0akJvOFZPNFlfb21fU1pFQ0pwNVJqdXRNZVRKTDVCQnZJXy1VVWFTQlE0S0ZzVjRKdW1IVWx3WTdJSERaNzk3alM3Zk53Mmd5QWpRcEQzcEdJWVJ0RktSalJXUGRtZk9reGVTbnhkMmo0SlE?oc=5","date":"2024-08-07","type":"pipeline","source":"globenewswire.com","summary":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight - globenewswire.com","headline":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNa3VvMmpoUldGVnZzaXR3aGl6SVgxbGIteFpXRzllZUQ0U1BxdUJnbDBUeXh3eGx0M0ZwUkJJdFhic3VMZnI3NWdjUldzTXdQNjJhbzVvNTY5X0NteWg0RHdSeWo0RTZxWEh2NXA0VExEbHlhMG1NYlE0ektQNjFpRlF1VXFQbHllbV9VSUJGOV8?oc=5","date":"2023-01-23","type":"pipeline","source":"seekingalpha.com","summary":"Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak - seekingalpha.com","headline":"Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5rVDFlam9Fd1Jvc0ZlaUR1a0wyZUtMc1lMSE1TdEQ3cnZBNDhfaklLcmtSTFFrSFc1SlZLem1rOEtqM2lFazY1bkVKU1l2ZndlMVc2TjRGakFzSXlwelc2YUF3?oc=5","date":"2022-11-02","type":"pipeline","source":"Straits Research","summary":"Stem Cells Market Size, Share, Growth | Industry Report, 2033 - Straits Research","headline":"Stem Cells Market Size, Share, Growth | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQU2NOT2xrSExfeFR0bVlmYTcxTzBzM1NkUnU2aTZyT2oyc1hqb2Z1V2h3UHVxYXBnR1RQcXdFSnRFTjdwQmpXN0dETFNtMTNzakl6VWZ5VWt4Tmhka1JOTlV2aHFhQWRBRDd0d1kzSEY1eENRTjZhQkFWVXkwcDFWcnlTOHRrSHk5SVY0bVBR?oc=5","date":"2022-07-24","type":"pipeline","source":"Yahoo Finance","summary":"Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries - Yahoo Finance","headline":"Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovativ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPRnB1WUtfaldsM2VnSHhWb0VvOEZFcDNFRzNuZUZDdWRKSndhR3ZKTDV4LXlzUDlVLWhVbUdQMzl6cUJ0RkoteE1OZjlMZEZ2b0tPNGdkd3RXLVVaNjYwWVRKU0l5SU92ck81TXBsUFd5RFBrNHNPWmwyYzExT0FMWm16UTF4Q2h6U05hQmJ2TE5ZMHJ1V192aw?oc=5","date":"2020-12-28","type":"pipeline","source":"New Trader U","summary":"Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U","headline":"Current Cathie Wood Portfolio 2020: Ark Invest Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBnaDNjZ0FYUGtqb0hCT0FrWDdZY2F3Ukh1SXpZSDJGTUVmOEJ3MUZnemt3bzV1T3ZTaHZzUGIzUHlkYWZVMWlkdHF6UGp6SWM2T2lkMURWOGJSeER3ak5JMFdLYUZIZkpu?oc=5","date":"2011-11-24","type":"pipeline","source":"גלובס","summary":"Oramed mulls dual listing on TASE, upgrading to AMEX - גלובס","headline":"Oramed mulls dual listing on TASE, upgrading to AMEX - גלובס","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}